AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
Medical Xpress on MSN15 天
New biomarkers could improve diagnosis and tracking of Parkinson's disease and Lewy body ...
Among patients with sporadic Parkinson's disease, 93% had NSD. The distribution for Stages 2B, 3, and 4 disease across these ...
Make this one lifestyle change to lower your Parkinson’s disease risk
There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong ...
Medical Xpress1 个月
Researchers identify a potential biomarker of Parkinson's disease progression
the main treatment for Parkinson's disease. Therefore, the exploration of new biomarkers is essential to accurately stratify patients, especially in the early stages, when the diagnosis is more ...
pharmaphorum10 天
PreciseDx AI diagnostic can detect early-stage Parkinson's
Diagnosing Parkinson's in the earliest stages before symptoms become serious ... for market and fund research into additional disease applications. The AI effect in pharma commercial strategy ...
AbbVie’s Phase III trial of Parkinson’s disease treatment meets primary endpoint
The company plans to submit a new drug application for tavapadon to the US Food and Drug Administration next year.